Menu Search

RTW Biotech Opportunities Ltd

RTW:LSE

RTW Biotech Opportunities Ltd

Actions
  • Price (USD)1.47
  • Today's Change-0.01 / -0.68%
  • Shares traded49.55k
  • 1 Year change+27.27%
  • Beta0.6435
Data delayed at least 20 minutes, as of Nov 22 2024 08:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year RTW Biotech Opportunities Ltd grew revenues 92.43% from 2.17m to 4.17m while net income improved from a loss of 39.44m to a gain of 83.19m.
Gross margin-97.57%
Net profit margin2,647.66%
Operating margin-123.07%
Return on assets22.87%
Return on equity25.65%
Return on investment25.28%
More ▼

Cash flow in USDView more

In 2023, RTW Biotech Opportunities Ltd increased its cash reserves by 107.84%, or 31.45m. The company earned 33.54m from its operations for a Cash Flow Margin of 804.22%. In addition the company used on investing activities and also paid 2.09m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share2.04
Tangible book value per share2.04
More ▼

Balance sheet in USDView more

RTW Biotech Opportunities Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 2.13%.
Current ratio--
Quick ratio--
Total debt/total equity0.0218
Total debt/total capital0.0213
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 312.71%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)17.97
EPS (TTM) vs
TTM 1 year ago		9.21
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.